|
市場調查報告書
生物工程業界受到不景氣影響
SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?
|
生物工程業界受到不景氣影響 是由出版商Decision Resources, Inc.在2009年05月所出版的。
這份英文市場調查報告書包含37 Pages 價格從美金6900起跳。
2008年金融危機為生物工程帶來很大的改變,許多企業瀕臨破產。但是,同一領域的民間投資仍然持續,製藥公司藉由多額投資,為了創造新藥產品及執行與有技術企業作合作和收購。
報告書內容包括:生物工程業界的合併、購買動向、企業間合作、對同領域的投資的重新評估等作統整。內容綱要摘記如下:
摘要
概要
公共資金和民間資金的供應
- 新股票公開的低迷
- 風險資本投資
- 具platform技術的治療藥廠商
- 治療platform企業
- 基礎標的治療藥廠商
- 研究階段的開發計畫動向
合併和收購
企業間的合作
- 交易的構造和交易總評價
- 目標和領導創藥
- 目標特定和評價
- 有和學術機構合作的目標特定和創藥
- 領導創藥交易
- 領導特定交易
- 領導最佳化交易
- 醫藥品.fragment選拔
- drug delivery
- dragprofiling
- 蛋白質最佳化交易
- 分子診斷交易
- 治療platfrom交易
對生物工程的投資作重新評估和動向掌握
圖表
Abstract
Introduction
In 2008, the global financial crisis radically altered the dynamics of the
biotech industry; many weaker companies will fail. However, private investment
in biotech continued, and pharmaceutical companies invested significant sums
in acquiring and partnering with biotech companies offering innovative
products and technologies for drug discovery.
Questions Answered in This Report
- Although the state of the economy is the dominant parameter that affects
all industries, the biotech industry is especially sensitive to economic
fluctuations. How are declines in capital markets affecting the biotech
industry? What are the current trends in biotech IPO activity?
- Despite the economic downturn, venture capital (VC) firms continued to
invest in biotechnology in 2008. What types of biotech companies are
attracting VC investments? Which technology areas attracted the most
investment? What types of start-up companies are able to obtain early-stage
financing?
- Mergers and acquisitions (M&As) have long been a litmus test of the
strategic objectives of pharmaceutical companies. M&As also have become an
important instrument for biotech companies that are seeking to survive or
become stronger. What are the current trends in pharma-biotech and
biotech-biotech M&As? What factors drove M&A activity in 2008?
- Corporate partnerships with pharmaceutical companies have become supremely
important to biotech companies as one of the few remaining sources of reliable
capital. What technology areas are attracting the interest of
pharmaceutical companies? What deal structures characterize current partnering
trends?
Scope
- Public equity financing: IPO downturn, focus of companies going
public in 2008.
- Private equity financing: VC investment, focus of companies, Series
A financings.
- Mergers and acquisitions: trends in recent high-value, strategic
pharma-biotech and biotech-biotech M&As, factors driving M&As, technologies of
acquired companies.
- Corporate partnerships: deal structure and value, target and lead
discovery, academic alliances, lead identification and optimization, lead
profiling, protein optimization, molecular diagnostics, therapeutic platforms.
- Outlook for biotech investment and trends: VC activity and focus,
areas of interest to Big Pharma, megadeals, profitability of biotech companies.
Mentioned in This Report
- Antibody humanization
- Antigen-binding artificial protein scaffolds
- Antisense
- Bioinformatics
- Cell therapy
- Chemistry focused screening
- Defucosylation
- Drug delivery
- Drug profiling
- Embryonic stem cells
- Formulation
- Fragment-based chemistry
- Fragmented antibodies
- Fusion proteins
- Glycosylation engineering
- Humanization
- In vitro display technologies
- Informatics
- Kinase inhibitors
- Lead identification
- Lead optimization
- Library-focused screening
- Liposome delivery
- Medicinal chemistry
- Micro RNA
- Molecular diagnostics
- Molecular signature analysis
- Monoclonal antibodies
- Nucleic-acid-based therapeutics
- Pharmacogenomics
- Protein engineering
- Protein interaction mapping
- Protein optimization
- Protein therapeutics
- RNA interference
- RNAi delivery systems
- Target-based approaches
- Target-focused screening
- Target identification
- Target validation
- Therapeutic antibodies
- Therapeutic platform technologies
- Transgenic animals
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview.
- Public and Private Equity Financing
- The IPO Downturn
- VC Investment
- Platform-Technology-Derived Therapeutic Companies
- Therapeutic Platform Companies
- Target-Based Therapeutic Companies
- Increasing Trend Toward Research-Stage Development Programs
- Mergers and Acquisitions
- Products and Pipelines as Drivers for M&A
- Platform Technologies as Drivers for M&A
- Corporate Partnerships
- Deal Structure and Assessing Deal Value
- Target and Lead Discovery
- Target Identification and Validation Deals
- Target Identification and Drug Discovery Through Academic Alliances
- Lead Discovery Deals
- Lead Identification Deals
- Target-Focused Screening
- Library- and Chemistry-Focused Screening
- Lead Optimization Deals
- Medicinal and Fragment-Based Screening
- Drug Delivery
- Drug Profiling
- Protein Optimization Deals
- Molecular Diagnostics Deals
- Therapeutic Platforms Deals
- Protein Therapeutics and Monoclonal Antibodies
- Nucleic-Acid-Based Therapeutics
- Cell Therapy
- Outlook for Biotech Investment and Trends
Tables
- 1. Biotechnology Initial Public Offerings, 2008
- 2. Blockbuster and Top-Selling Drugs Acquired Through Pharma-Biotech
Acquisitions
- 3. Blockbuster and Top-Selling Drugs Acquired Through Biotech-Biotech
Acquisitions
- 4. Select Target Discovery Corporate Partnerships, 2008
- 5. Select Academic Drug Discovery and Research Alliances, 2008
- 6. Select Lead Identification Corporate Partnerships, 2008
- 7. Select Lead Optimization Corporate Partnerships, 2008
- 8. Select Protein Optimization Corporate Partnerships, 2008
- 9. Select Molecular Diagnostics Partnerships, 2008
- 10. Select Therapeutic Platform Corporate Partnerships, 2008
Figures
- 1. Biotech Quarterly Initial Public Offerings and Venture Capital
Investments, 2002-2008
- 2. Life-Sciences-Related Venture Capital Investments, 2008
- 3. Technology Focus of Biotech Series A Companies, 2008
- 4. Developmental Stage of Therapeutic Biotech Companies with Series A
Investments, 2005 and 2008
- 5. Biotechnology M&As Worth More Than $100 Million, 2002-2008
|
